A drug combination targeting multiple mutant versions of cancer’s “death star” protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer.
The two–drug combination was effective against advanced cancers with a range of mutations to the KRAS gene—dubbed the “death star” because its protein drives one in four cancers and has a largely impenetrable, drug-resistant surface.
The phase I trial tested the drugs VS-6766 and everolimus in 30 patients with a range of mutations to KRAS—including 11 with highly advanced, non-small cell lung cancer.
Comments are closed.